Search alternatives:
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
200 mg » 100 mg (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
200 mg » 100 mg (Expand Search)
-
1
Baseline characteristics of participants.
Published 2025“…Dyslipidemia was characterized by meeting the following criteria: having at least one claim of International Classification of Diseases (ICD)-10 code (E78) with an anti-dyslipidemia agent prescription, claims of ICD-10 code (E78) occurring more than twice, a total cholesterol level ≥ 240 mg/dL, low-density lipoprotein cholesterol ≥ 160 mg/dL, triglycerides ≥ 200 mg/dL, or high-density lipoprotein cholesterol < 40 mg/dL. …”
-
2
-
3
-
4
-
5
-
6
Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial
Published 2010“…Adult outpatients presenting influenza-like illness for less than 36 hours and a positive influenza A rapid test diagnosis were randomized to oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (OZ), oseltamivir plus inhaled placebo (O), or zanamivir plus oral placebo (Z). …”
-
7
-
8
-
9
DataSheet_2_Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial.docx
Published 2022“…Adult AS patients with BASDAI ≥4 or ASDAS ≥2.1, CRP >6 mg/L, or ESR 28 mm/1st hour were randomly assigned (1:1:1 ratio) to celecoxib 200 mg bid or etanercept 50 mg qw or combined therapy for 52 weeks. …”
-
10
DataSheet_1_Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial.docx
Published 2022“…Adult AS patients with BASDAI ≥4 or ASDAS ≥2.1, CRP >6 mg/L, or ESR 28 mm/1st hour were randomly assigned (1:1:1 ratio) to celecoxib 200 mg bid or etanercept 50 mg qw or combined therapy for 52 weeks. …”
-
11
Supplementary Material for: Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma
Published 2015“…The maximum tolerated dose of sorafenib was 200 mg BID. Grade 3-4 toxicities seen in >10% of subjects included leukopenia (21%), elevated gamma-glutamyl transferase (21%), hypertension (14%), hand-foot syndrome (14%) and diarrhea (14%). …”
-
12
-
13
-
14
CyclinD1 transcriptional repression by T3 implicates thyroid hormone receptor α1 (TRα1)
Published 2011“…Luciferase assays were performed 18 h later. T3 treatment induces a strong decrease in cyclinD1-luciferase expression compared to the control group. () Different doses (ranging from 2 to 200 nM) of siRNAs directed against TRα1 (siTRα1) were co-injected along with the CyclinD1-luciferase plasmid in the lateral ventricles of euthyroid newborn mice, inducing a strong activation of CyclinD1-luciferase expression. () The same experiment as described in (c) was performed by using plasmids coding for shTRα1 instead of siTRα1. …”
-
15
-
16
-
17
-
18
<b>Tirzepatide Associated with Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Cli...
Published 2025“…To examine the generalizability of these findings, we assessed change from baseline in UACR for tirzepatide (5, 10, and 15 mg) compared with active and placebo treatment in a broad population from the SURPASS-1-5 trials.…”
-
19
Increased synaptosomal Nox-2 activation and superoxide production in old wild-type mice is absent in old IL-6-/- mice; determination by electrochemical oxygen consumption analysis...
Published 2009“…<p>(a) NADPH-induced oxygen consumption is significantly decreased by the Nox inhibitor apocynin (300 µM, black bars). …”
-
20